RE:CellPress: Emerging Field of OV Based Cancer ImmunotherapyCombination therapy with PD-L! immune checkpoint inhibitors is beginning to demonstrate extended patient survival. October 15, 2024 - It's quite the turn of events for Jazz Pharmaceuticals’ Zepzelca, - once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer (ES-SCLC).
Zepzelca, used in combination with Roche’s Tecentriq, outperformed Tecentriq alone when used as a first-line maintenance treatment in ES-SCLC following induction therapy with Tecentriq and chemo, Jazz said Tuesday.
The addition of Zepzelca delayed disease progression and extended survival, leading to a statistically significant improvement in both overall survival and progression-free survival by independent review in the phase 3 IMforte trial.
While keeping Zepzelca’s accelerated approval in place, the FDA accepted Jazz’s proposal of two new trials to confirm Zepzelca’s efficacy, and one of them is IMforte. The trial had previously carried a primary completion date in September 2025.
https://www.fiercepharma.com/pharma/jazzs-almost-withdrawn-lung-cancer-drug-zepzelca-extends-life-top-roches-tecentriq